Mazdutide
Also known as: IBI362, LY3305677, IBI-362, LY-3305677, OXM-3
Classification
Peptide
Regulatory Status
n/a
Sources
4
Review
n/a
Overview
Mazdutide is described as a dual agonist of the glucagon receptor and the GLP-1 receptor (oxyntomodulin-analog class).
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Interactions & cautions
Drug interactions
other GLP-1 receptor agonists and insulin/secretagogues — Expected class overlap with incretin therapies (GI effects, glycemic potentiation risk with insulin/secretagogues); no US label interaction table. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw